Back to Journals » Vascular Health and Risk Management » Volume 9

Metabolic biomarkers for predicting cardiovascular disease

Authors Montgomery J, Brown J

Received 3 October 2012

Accepted for publication 30 November 2012

Published 29 January 2013 Volume 2013:9 Pages 37—45


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Jana E Montgomery,1,2 Jeremiah R Brown1–3

1Dartmouth-Hitchcock Medical Center, Division of Cardiology, Lebanon, NH, USA; 2Geisel School of Medicine, Hanover, NH, USA; 3The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, USA

Abstract: Cardiac and peripheral vascular biomarkers are increasingly becoming targets of both research and clinical practice. As of 2008, cardiovascular-related medical care accounts for greater than 20% of all the economic costs of illness in the United States. In the age of burgeoning financial pressures on the entire health care system, never has it been more important to try to understand who is at risk for cardiovascular disease in order to prevent new events. In this paper, we will discuss the cost of cardiovascular disease to society, clarify the definition of and need for biomarkers, offer an example of a current biomarker, namely high-sensitivity C-reactive protein, and finally examine the approval process for utilizing these in clinical practice.

Keywords: cardiac biomarkers, cardiovascular disease

Creative Commons License © 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.